Thanapluetiwong Saran, Chattaris Tanchanok, Shi Sandra Miao, Park Chan Mi, Sison Stephanie Denise M, Kim Dae Hyun
Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA.
Ann Geriatr Med Res. 2024 Sep;28(3):247-256. doi: 10.4235/agmr.24.0034. Epub 2024 May 17.
Medication is a potential factor influencing frailty. However, the relationship between pharmaceutical treatments and frailty remains unclear. Therefore, we conducted the present systematic review to summarize the association between drug therapy and the risk of incident frailty in older adults. We systematically searched the MEDLINE electronic database for articles indexed between January 1, 2000, and December 31, 2021, for randomized controlled trials (RCTs) and cohort studies reporting frailty changes associated with drug therapy. A total of six RCTs and 13 cohort studies involving 211,948 participants were identified, and their treatments were categorized into six medication classes: analgesics, cardiometabolic medication, chemotherapy, central nervous system (CNS)-active medication, hormonal therapy, and nutritional supplements. While the analysis revealed that only CNS-active medications were associated with an elevated risk of frailty, other medication classes also affected frailty; however, this is not conclusively attributable to a class-wide effect.
药物治疗是影响衰弱的一个潜在因素。然而,药物治疗与衰弱之间的关系仍不明确。因此,我们进行了本系统评价,以总结药物治疗与老年人发生衰弱风险之间的关联。我们系统地检索了MEDLINE电子数据库,查找2000年1月1日至2021年12月31日期间索引的文章,以获取报告与药物治疗相关的衰弱变化的随机对照试验(RCT)和队列研究。共确定了6项RCT和13项队列研究,涉及211,948名参与者,其治疗方法分为六类药物:镇痛药、心脏代谢药物、化疗药物、中枢神经系统(CNS)活性药物、激素疗法和营养补充剂。虽然分析显示只有中枢神经系统活性药物与衰弱风险升高有关,但其他药物类别也会影响衰弱;然而,这不能完全归因于全类效应。